This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Doolittle, N. D. Articles by Neuwelt, E. A. Search for Related Content PubMed PubMed Citation Articles by Doolittle, N. D. Articles by Neuwelt, E. A.

Targeted Delivery in Primary and Metastatic Brain Tumors

Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium¹

Oregon Health and Science University, Department of Neurology, Portland, Oregon 97201-3098 [N. D. D., L. L. M., E. A. N.]; Memorial Sloan-Kettering Cancer Center, Department of Neurology, New York, New York 10021 [L. E. A.]; Neuro-oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 [N. F.]; University of Minnesota, Department of Neurosurgery, Minneapolis, Minnesota 55455 [W. A. H.]; University of Virginia, Department of Neurosurgery, Charlottesville, Virginia 22903 [E. R. L.]; Duke University Medical Center, Pathology Department, Durham, North Carolina 27710 [R. E. M.]; Cleveland Clinic Foundation, Hematology & Medical Oncology, Cleveland, Ohio 44195 [D. P.]; The Chicago Medical School, Department of Physiology and Biophysics, North Chicago, Illinois 60064 [D. R. P.]; Childrens Hospital Los Angeles, Division of Hematology/Oncology, Los Angeles, California 90027-6062 [C. P. R.]; and Seattle Genetics, Inc., Bothell, Washington 98021 [P. S.]

ABSTRACT

The November 2000 NIH report of the Brain Tumor ProgressReview Group identified delivering and targeting therapeutic agents as a priority in the treatment of malignant brain tumors. For this reason, the seventh annual Blood-Brain Barrier Disruption Consortium meeting, partially funded by an NIH R13 Grant, focused on recent advances in targeted delivery to the central nervous system, clinical trials for primary and metastatic brain tumors using enhanced chemotherapy delivery, and strategies to lessen the toxicities associated with dose intensive treatments, using thiols.